Circio Holding is trading 13.78% up at NOK 14.70 after its August 31 first-half report highlighted major R&D gains and approximately NOK 620 million in new capital.

  • circVec expression was up to 60-fold higher in CNS tissue; potential heart-expression gains exceeded 200-fold.
  • The company reported durable non-viral in-vivo CAR-T expression, with cash runway extended through 2030.
  • A September 1 webcast will provide further R&D details.